Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IVISense Acute Vascular 750 fluorescent probe is small molecule near infrared fluorescent agent designed for in vivo preclinical intravenous (IV) administration. This probe, being of low molecular weight, rapidly leaks into regions of increased vascular permeability that can occur due to cancer or inflammation. In addition, its rapid clearance from the blood allows early imaging of the bladder or ureters for basic research or for surgical imaging approaches in small and large animals. The physical/chemical properties of this probe also makes it useful for encapsulation into nanoparticles or liposomes as a reporter system for drug delivery approaches.
This fluorescent probe is available in a 5 mg size.
|Fluorescent Agent Type||Vascular|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Unit Size||5 mg|
|Wave Length||750 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
Genhance™ 750 is the acid form of VivoTag-S® 750 that can be used as a control or a fluorescent in vivo blood pool imaging agent.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.